Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
2002 1
2003 2
2004 1
2005 3
2006 3
2007 4
2009 3
2010 4
2011 2
2012 4
2013 9
2014 11
2015 7
2016 5
2017 4
2018 7
2019 20
2020 13
2021 19
2022 21
2023 24
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
[Simulation model of tumor-treating fields].
Qin L, Xie X, Wang M, Ma M, Pan Y, Chen G, Zhang S. Qin L, et al. Among authors: xie x. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2024 Apr 25;41(2):360-367. doi: 10.7507/1001-5515.202306074. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2024. PMID: 38686418 Free PMC article. Chinese.
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
Coates LC, Gossec L, Zimmermann M, Shawi M, Rampakakis E, Shiff NJ, Kollmeier AP, Xu XL, Nash P, Mease PJ, Helliwell PS. Coates LC, et al. Among authors: xu xl. RMD Open. 2024 Mar 26;10(1):e003977. doi: 10.1136/rmdopen-2023-003977. RMD Open. 2024. PMID: 38531621 Free PMC article. Clinical Trial.
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
Rahman P, McInnes IB, Deodhar A, Schett G, Mease PJ, Shawi M, Cua DJ, Sherlock JP, Kollmeier AP, Xu XL, Sheng S, Ritchlin CT, McGonagle D. Rahman P, et al. Among authors: xu xl. Clin Rheumatol. 2024 May;43(5):1591-1604. doi: 10.1007/s10067-024-06921-8. Epub 2024 Mar 12. Clin Rheumatol. 2024. PMID: 38472528 Free PMC article.
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study.
Coates LC, Rahman P, Mease PJ, Shawi M, Rampakakis E, Kollmeier AP, Xu XL, Chakravarty SD, McInnes IB, Tam LS. Coates LC, et al. Among authors: xu xl. BMC Rheumatol. 2024 Feb 4;8(1):6. doi: 10.1186/s41927-024-00375-w. BMC Rheumatol. 2024. PMID: 38310261 Free PMC article.
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
Siebert S, Coates LC, Schett G, Raychaudhuri SP, Chen W, Gao S, Seridi L, Chakravarty SD, Shawi M, Lavie F, Sharaf M, Zimmermann M, Kollmeier AP, Xu XL, Rahman P, Mease PJ, Deodhar A. Siebert S, et al. Among authors: xu xl. Arthritis Rheumatol. 2024 Jan 22. doi: 10.1002/art.42803. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 38253404
163 results